MICIN Co., Ltd. Abbott and MICIN start collaboration to build a new treatment environment for diabetes

MICIN Co., Ltd.
Abbott and MICIN Collaborate to Build a New Treatment Environment for Diabetes
● By combining self-monitoring blood glucose devices such as Abbott’s continuous glucose meter FreeStyle Libre with MICIN’s online medical service curon, we provide a new treatment environment for people with diabetes and those who need blood sugar management. To go.
● The two companies will jointly provide solutions that make it easier and more efficient for people with diabetes and those who need to manage their blood sugar to manage their diabetes in their daily lives, and make it easier for them to receive appropriate treatment from their doctors. I’m planning to do it.
October 12, 2022- Abbott Japan GK (Headquarters: Minato-ku, Tokyo; President and CEO: Hideyuki Takechi; hereinafter “Abbott”) and MICIN Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; CEO: Seigo Hara) , hereinafter referred to as “MICIN”) is pleased to announce that it has started a collaboration to build a new treatment environment for diabetes in Japan.
The two companies will jointly develop disease awareness activities to raise awareness of the importance of continued treatment, which has become an important issue for diabetes, especially type 2 diabetes. As the first step, we will start a new initiative called “blood sugar fluctuation monitoring” by online medical treatment. The initiative will make it easier for patients to find medical providers that offer online consultations where they can get advice on managing their blood sugar. You can also receive medical treatment remotely through the online medical service curon. At the same time, we have released a special page on curon where people with diabetes, those who need blood sugar control, and those who are interested in “blood sugar
fluctuation monitoring” can understand remote blood sugar control. . Diabetes is a chronic disease that, if left untreated, interrupted, or not properly managed and treated, not only worsens, but also causes heart disease, vision loss, and kidney disease. There is a possibility of developing serious complications such as (* 1). On the other hand, 42.4% of working-age people with diabetes have not been treated (*2), and less than one-third of those who have received treatment have discontinued treatment. are not receiving adequate treatment (*3). In addition, due to the epidemic of the new coronavirus infection, many people are refraining from seeing a doctor, which has become a social problem.
Busyness is cited as the main reason people with diabetes discontinue treatment. is expected. In addition, self-monitoring blood glucose monitors, such as Abbott’s FreeStyle Libre continuous glucose monitor, can continuously monitor and remotely share blood glucose information, which is important for diabetes treatment, to monitor blood glucose levels in the comfort of your own home. Get healthcare professional advice on management and get the right diabetes care.
Abbott and MICIN are aware of the current situation in which it is difficult to receive appropriate medical examinations due to the corona crisis, and that the coverage of FreeStyle Libre’s insurance coverage category C150 blood glucose self-monitoring device addition 7 has been expanded to all people with diabetes who are on insulin therapy, and Based on the revision of the medical fee system and the review of online medical fees, we have decided to start a
collaboration for the development of diabetes treatment in Japan. Seigo Hara, CEO of MICIN said: “Chronic diseases such as diabetes require continuous care and regular medical examinations, so digital interventions and online medical consultations are expected to reduce the burden. Abbott, the world leader in continuous glucose measurement technology I hope that by working on this, we will be able to provide better treatment support for as many people with diabetes as possible.”
Caroline Johnson, General Manager, Diabetes Care Division, Abbott Japan G.K. “Abbott is committed to working with a variety of partners to deliver innovative solutions to the treatment of diabetes. By combining MICIN’s online medical treatment platform curon, we believe that we can provide a digital solution that enables a treatment environment suitable for each person without feeling annoyed in their daily lives.”
About FreeStyle Libre
Abbott’s FreeStyle Libre is the world’s leading device for continuous glucose monitoring technology(4), used by nearly 4 million people in more than 60 countries(5). FreeStyle Libre users can use the FreeStyle Libre Link app to quickly and discreetly scan the sensor using their smartphone. People with diabetes can also share their blood sugar data with their doctors via LibreView.
FreeStyle Libre received manufacturing and marketing approval in Japan in May 2016 and was launched in January 2017. FreeStyle Libre is a C150 blood glucose self-monitoring supplement for patients other than hospitalized patients who self-inject insulin preparations at least once a day, regardless of type 1 or type 2. by an intermittent scanning continuous blood glucose meter” will be applied.
About curon
Clone, which was launched by MICIN Co., Ltd. in April 2016, is a leading online medical treatment service in Japan, and as of September 2022, it has been introduced at more than 6,000 medical institutions. With Kron, patients can use smartphones, PCs, and tablets, and medical institutions can use PCs or tablet terminals, and can complete everything from reservations to medical interviews, examinations, payments, and delivery procedures for prescriptions and medicines online. In addition, it is linked with MICIN’s online medication guidance service for pharmacies, “curon (Kuron) medicine support”, and patients can receive online medication guidance, payment, and medicine delivery services from pharmacists on the same Curon app. can do. About Abbott
Abbott is a global healthcare leader that helps people live their best lives at every stage of life. Including industry-leading diagnostics and devices, medical devices, nutritionals and branded generic businesses and products, Abbott’s breakthrough technologies that have a profound impact on people’s lives span a broad spectrum of healthcare. It’s over. Currently, about 113,000 employees are active in more than 160 countries around the world.
Abbott (https://www.abbott.com/), Abbott Japan
(https://www.abbott.co.jp/), LinkedIn
(https://www.linkedin.com/company/abbott-/) , Facebook
(https://www.facebook.com/Abbott), and Twitter
MICIN Co., Ltd. is a company founded in 2015 with the vision of “a world where everyone can live with satisfaction and face the end.” We will establish a small amount short-term insurance company in 2021 to develop and provide new insurance services, as well as a medical business that provides online medical services for medical
institutions and pharmacies, develops digital therapeutics, and provides solutions for clinical development. going. Company URL: https://micin.jp/
(*1) Centers for Disease Control and Prevention “What is Diabetes?” (https://www.cdc.gov/diabetes/basics/diabetes.html)
(*2) 2017 National Health and Nutrition Survey
(*3) 2019 National Health and Nutrition Survey
(*4) Abbott research.
(*5) Abbott research.
Details about this release:

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: